The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Brentuximab vedotin plus lenalidomide and rituximab for R/R DLBCL: Results from the ECHELON-3
|
Results from the phase III ECHELON-3 trial (NCT04404283) of brentuximab vedotin (BV) plus lenalidomide(Len) and rituximab (R) vs placebo (Pbo) plus Len and R in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received ≥2 prior lines of systemic therapy were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Jeong.1 |
| Key learnings: |
|
The phase III ECHELON-3 trial met its primary endpoint of overall survival (OS). |
|
The OS was 13.8 months (median follow up [mFU], 15.5 months) vs 8.5 months (mFU, 18.9 months) in the BV+Len+R and Pbo+Len+R arms, respectively (HR, 0.629; 95% confidence interval [CI] 0.445–0.891; p = 0.0085). |
|
BV+Len+R was associated with improved progression-free survival (PFS) and a higher complete response rate vs Pbo+Len+R: mPFS was 4.2 months vs 2.6 months (HR, 0.527; 95% CI, 0.380–0.729; p < 0.0001) and the ORR rates were 64.3% vs 41.5% (p < 0.0006), respectively. |
|
The safety profile of BV+Len+R was consistent with that of the individual agents. |
| The results from the ECHELON-3 trial suggest that BV+Len+R could be a viable therapeutic option for the treatment of patients with R/R DLBCL, particularly those who cannot receive CAR T-cell therapy or bispecific antibodies or have R/R disease after these treatments. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
